Adrenoleukodystrophy pathophysiology

Jump to navigation Jump to search

Adrenoleukodystrophy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenoleukodystrophy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Adrenoleukodystrophy pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenoleukodystrophy pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenoleukodystrophy pathophysiology

CDC on Adrenoleukodystrophy pathophysiology

Adrenoleukodystrophy pathophysiology in the news

Blogs on Adrenoleukodystrophy pathophysiology

Directions to Hospitals Treating Adrenoleukodystrophy

Risk calculators and risk factors for Adrenoleukodystrophy pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Overview

Adrenoleukodystrophy is an X-linked disease characterized by excessive accumulation of very long chain fatty acids (VLCFA), originally described by Moser et al in 1981. The gene, ABCD1, transfers fatty acids into peroxisomes to undergo β-oxidation. However, VLCFA accumulation is necessary but not sufficient for the pathogenesis. The CNS pathology suggests the role of cellular and humoral immune processes.

Pathophysiology

Physiology

The most common form of ALD is X-linked (the defective gene is on the X chromosome, location Xq28), and is characterized by excessive accumulation of very long chain fatty acids (VLCFA) — fatty acids chains with 24–30 carbon atoms (particularly hexacosanoate, C26) in length. This was originally described by Moser et al in 1981.[1] So, when the ALD gene was discovered in 1993, it was a surprise that the corresponding protein was in fact a member of a family of transporter proteins, not an enzyme. It is still a mystery as to how the transporter affects the function of the fatty acid enzyme and, for that matter, how high levels of very long chain fatty acids cause the loss of myelin on nerve fibers.

Pathogenesis

Pathology in CNS shows distinct immunological features. A predominant Th1 cytokine response suggests the role of cell mediated immunity. Immunocytochemical analysis done on the CSF from the ALD patients showed IgG, B cells and the presence of cytoplasmic IgA in postmortem brain suggesting the role of the humoral immune process. There was increased expression of the antigen-presenting molecule, which presents foreign and self-lipid to MHC-unrestricted T cells, CD1 in cerebral lesions clearly showing that both VLCFA and a myelin component such as proteolipid protein serves as the antigen for the immune response. [2] TNF-alpha also has an important role in the pathogenesis of ALD.

Genetics

The gene (ABCD1 or "ATP-binding cassette, subfamily D, member 1") codes for a protein that transfers fatty acids into peroxisomes, the cellular organelles where the fatty acids undergo β-oxidation.[3] A dysfunctional gene leads to the accumulation of very long chain fatty acids (VLCFA).

Gross pathology

  • Adrenal glands show atrophy.
  • Brain shows visible demyelination involving both cerebellar hemispheres, parts of the medulla oblongata, the pons and the midbrain.
  • Spinal cord shows grayish white matter area.

Microscopic Pathology

Adrenals

Medulla appears fine, but the cortex is atrophic. A substantial portion of it is replaced by clusters of extremely large cells, distinctly delimited from each other, with mildly granular eosinophilic cells.Cytoplasm and a nucleus moderately rich in chromatin shifted towards the cytoplasma membrane.[4]

Nervous System[4]

  • Nearly complete demyelination involving all white structures in the dorsal parts of the brainstem.
  • Complete demyelination in cerebellar hemispheres, cerebral peduncles, the pes pontis, pyramids and the lateral pyramidal tract.
  • Gliosis and macrophages present. Glial cells distributed in myelinated and unmyelinated areas.
  • Abnormalities observed in schwann cells in the peripheral nerves.
  • Changes in the gray matter are less apparent than those in white matter but some of the pathological findings present include:
    • Proximal Axonal Swellings in Purkinje cell axons
    • Ballooned nerve cells in the arcuate nucleus of the medulla oblongata
    • Granular cellular content and nucleus displaced towards the periphery

References

  1. Moser HW, Moser AB, Frayer KK, Chen W, Schulman JD, O'Neill BP, Kishimoto Y. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 1981;31:1241-9. PMID 7202134.
  2. Hudspeth, Michelle P.; Raymond, Gerald V. (2007). "Immunopathogenesis of adrenoleukodystrophy: Current understanding". Journal of Neuroimmunology. 182 (1–2): 5–12. doi:10.1016/j.jneuroim.2006.10.009. ISSN 0165-5728.
  3. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, Poustka AM, Mandel JL, Aubourg P. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993;361:726-30. PMID 8441467.
  4. 4.0 4.1 Ulrich, J.; Herschkowitz, N.; Heitz, Ph.; Sigrist, Th.; Baerlocher, P. (1978). "Adrenoleukodystrophy". Acta Neuropathologica. 43 (1–2): 77–83. doi:10.1007/BF00685001. ISSN 0001-6322.

Template:WH Template:WS